Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus paclitaxel versus placebo plus paclitaxel in untreated advanced triple-negative breast cancer
MOH_2017-06-02_000477Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in triple-negative breast cancer (TNBC) comparing Atezolizumab plus paclitaxel with Placebo plus paclitaxel (2 arms). Started May 2017; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on MOH_2017-06-02_000477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-02_000477.